Prev: Recent review articles about pancreatic cancer (InTextoResearch)
Next: What's your doc thinking? Web site offers clues
From: scimedweb on 2 Aug 2008 14:30
Recent review articles about prostate cancer:

Targeted therapy of cancer: new roles for pathologists--prostate
cancer.
Rubin MA.
Mod Pathol. 2008 May;21 Suppl 2:S44-55.

Prostate cancer stem cells: a new target for therapy.
Maitland NJ, Collins AT.
J Clin Oncol. 2008 Jun 10;26(17):2862-70.

Prostate carcinoma and radiation therapy: therapeutic treatment
resistance and strategies for targeted therapeutic intervention.
Fitzgerald TJ, Wang T, Goel HL, Huang J, Stein G, Lian J, Davis RJ,
Doxsey S, Balaji KC, Aronowitz J, Languino LR.
Expert Rev Anticancer Ther. 2008 Jun;8(6):967-74.

Androgen receptor coactivators and prostate cancer.
Agoulnik IU, Weigel NL.
Adv Exp Med Biol. 2008;617:245-55.

Castration-recurrent prostate cancer is not androgen-independent.
Mohler JL.
Adv Exp Med Biol. 2008;617:223-34.

Strategy for the application of therapy in prostate cancer.
Logothetis CJ.
Adv Exp Med Biol. 2008;617:193-9.

Prostate cancer susceptibility loci: finding the genes.
Ostrander EA, Johannesson B.
Adv Exp Med Biol. 2008;617:179-90.

Hormone refractory prostate cancer: Lessons learned from the PTEN
prostate cancer model.
Mulholland DJ, Jiao J, Wu H.
Adv Exp Med Biol. 2008;617:87-95.

Newer imaging modalities to assist with target localization in the
radiation treatment of prostate cancer and possible lymph node
metastases.
John SS, Zietman AL, Shipley WU, Harisinghani MG.
Int J Radiat Oncol Biol Phys. 2008;71(1 Suppl):S43-7.

Prostate cancer.
Damber JE, Aus G.
Lancet. 2008 May 17;371(9625):1710-21.

Clinical trials of cancer therapies targeting prostate-specific
membrane antigen.
Olson WC, Heston WD, Rajasekaran AK.
Rev Recent Clin Trials. 2007 Sep;2(3):182-90.

CYP17 inhibitors for prostate cancer treatment--an update.
Moreira VM, Salvador JA, Vasaitis TS, Njar VC.
Curr Med Chem. 2008;15(9):868-99.

Stem cells: The root of prostate cancer?
Kasper S.
J Cell Physiol. 2008 Aug;216(2):332-6.

Microarrays--identifying molecular portraits for prostate tumors with
different Gleason patterns.
Mendes A, Scott RJ, Moscato P.
Methods Mol Med. 2008;141:131-51.

Poor usage of HUGO standard gene nomenclature in cancer marker
studies.
Lacroix M.
Int J Biol Markers. 2008 April - June;23(2):123-126.

Androgens and the molecular epidemiology of prostate cancer.
Chu LW, Reichardt JK, Hsing AW.
Curr Opin Endocrinol Diabetes Obes. 2008 Jun;15(3):261-70.

WWOX tumor suppressor gene.
Yang J, Zhang W.
Histol Histopathol. 2008 Jul;23(7):877-82.

Involvement of the chromatin-remodeling factor BRG1/SMARCA4 in human
cancer.
Medina PP, Cespedes MS.
Epigenetics. 2008 Mar-Apr;3(2):64-8.

Five-alpha-reductase Inhibitors for prostate cancer prevention.
Wilt TJ, MacDonald R, Hagerty K, Schellhammer P, Kramer BS.
Cochrane Database Syst Rev. 2008 Apr 16;(2):CD007091.

How much of the data published in observational studies of the
association between diet and prostate or bladder cancer is usable for
meta-analysis?
Bekkering GE, Harris RJ, Thomas S, Mayer AM, Beynon R, Ness AR,
Harbord RM, Bain C, Smith GD, Sterne JA.
Am J Epidemiol. 2008 May 1;167(9):1017-26.

Prostate stem cells and benign prostatic hyperplasia.
Isaacs JT.
Prostate. 2008 Jun 15;68(9):1025-34.


(contact at InTextoResearch: Marc Lacroix, Baelen, Wallonia, Belgium -
scimedweb(a)mail.com)
 | 
Pages: 1
Prev: Recent review articles about pancreatic cancer (InTextoResearch)
Next: What's your doc thinking? Web site offers clues